ORIC Pharmaceuticals, Inc. (ORIC) Ownership
ORIC ownership summary
as of October 18, 2026- Institutions
- 123.4% of shares outstanding
- Insiders
- 1.59% of shares outstanding
- Shares outstanding
- 103.7M
- Float
- 88.7M shares available to trade
- Short interest
- 15.91% 16.3M shares short
- Days to cover
- 11.16 short interest down 6.9% vs prior month
- Institutions 123.41%
- Insiders 1.59%
ORIC top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Nextech Invest, Ltd. | 6.91% | 7.2M | $88.5M | — | June 30, 2026 |
| 2 | BlackRock Inc | 6.58% | 6.8M | $84.3M | +839,421 (+14.0%) | June 30, 2026 |
| 3 | EcoR1 Capital, LLC | 6.49% | 6.7M | $83.1M | — | June 30, 2026 |
| 4 | T. Rowe Price Associates, Inc. | 6.38% | 6.6M | $81.7M | +1.2M (+22.8%) | June 30, 2026 |
| 5 | Viking Global Investors LP | 4.95% | 5.1M | $63.3M | −697,771 (−12.0%) | June 30, 2026 |
| 6 | State Street Corp | 4.72% | 4.9M | $60.4M | +1.2M (+32.2%) | June 30, 2026 |
| 7 | SR ONE CAPITAL MANAGEMENT, LP | 4.45% | 4.6M | $57.0M | +100,455 (+2.2%) | June 30, 2026 |
| 8 | VR Adviser, LLC | 4.17% | 4.3M | $53.3M | — | June 30, 2026 |
| 9 | NEA Management Company, LLC | 3.97% | 4.1M | $50.9M | — | June 30, 2026 |
| 10 | Vanguard Capital Management, LLC | 3.81% | 4.0M | $48.8M | +264,162 (+7.2%) | June 30, 2026 |
| 11 | AIHC Capital Management Limited | 3.69% | 3.8M | $47.3M | +1.4M (+55.7%) | June 30, 2026 |
| 12 | Alkeon Capital Management, LLC | 3.61% | 3.7M | $46.2M | −765,000 (−17.0%) | June 30, 2026 |
| 13 | Column Group LLC | 3.42% | 3.5M | $43.7M | — | June 30, 2026 |
| 14 | Siren, L.L.C. | 2.89% | 3.0M | $37.0M | — | June 30, 2026 |
| 15 | FMR Inc | 2.54% | 2.6M | $32.5M | +201,395 (+8.3%) | June 30, 2026 |
| 16 | Citadel Advisors Llc | 2.50% | 2.6M | $32.1M | +172,558 (+7.1%) | June 30, 2026 |
| 17 | The Goldman Sachs Group Inc | 2.37% | 2.5M | $30.3M | +976,084 (+66.1%) | June 30, 2026 |
| 18 | Geode Capital Management, LLC | 2.02% | 2.1M | $25.8M | +251,288 (+13.7%) | June 30, 2026 |
| 19 | First Turn Management LLC | 1.95% | 2.0M | $24.9M | — | June 30, 2026 |
| 20 | Orbimed Advisors LLC | 1.94% | 2.0M | $24.9M | −678,929 (−25.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 10 holders added 6.6M shares and 3 cut 2.1M.
ORIC top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.86% | 3.0M | $36.6M | — | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.35% | 2.4M | $30.1M | −46,500 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 1.87% | 1.9M | $23.9M | −22,336 (−1.1%) | September 30, 2026 |
| 4 | ACAP Strategic A | 1.79% | 1.9M | $22.9M | −375,597 (−16.9%) | June 30, 2026 |
| 5 | T. Rowe Price Integrated US Sm Gr Eq | 1.22% | 1.3M | $15.6M | — | August 31, 2026 |
| 6 | Franklin Biotechnology Discv A(acc)USD | 1.18% | 1.2M | $15.1M | — | August 31, 2026 |
| 7 | T. Rowe Price Health Sciences | 1.15% | 1.2M | $14.8M | −336,100 (−21.9%) | August 31, 2026 |
| 8 | T. Rowe Price New Horizons | 0.98% | 1.0M | $12.5M | −41,483 (−3.9%) | August 31, 2026 |
| 9 | Eventide Healthcare & Life Sciences I | 0.92% | 951K | $11.8M | — | June 30, 2026 |
| 10 | Fidelity Small Cap Index | 0.79% | 818K | $10.1M | +6,520 (+0.8%) | July 31, 2026 |
| 11 | Fidelity Growth Company Fund | 0.69% | 717K | $8.9M | — | August 31, 2026 |
| 12 | Biotech Growth Ord | 0.65% | 674K | $8.3M | −296,833 (−30.6%) | June 30, 2026 |
| 13 | Franklin Biotechnology Discovery A | 0.64% | 659K | $8.1M | — | August 31, 2026 |
| 14 | iShares Biotechnology ETF | 0.51% | 532K | $6.6M | −4,032 (−0.8%) | September 30, 2026 |
| 15 | Vanguard Explorer Inv | 0.51% | 527K | $6.5M | +526,858 (0.0%) | June 30, 2026 |
| 16 | iShares Russell 2000 Value ETF | 0.47% | 485K | $6.0M | +736 (+0.2%) | September 30, 2026 |
| 17 | Schwab US Small-Cap ETF™ | 0.46% | 479K | $5.9M | +315 (+0.1%) | September 30, 2026 |
| 18 | Vanguard Russell 2000 ETF | 0.41% | 429K | $5.3M | +9,981 (+2.4%) | August 31, 2026 |
| 19 | Belfius Equities Cure C Cap | 0.41% | 420K | $5.2M | — | March 31, 2026 |
| 20 | Nuveen Quant Small Cap Equity R6 | 0.39% | 405K | $5.0M | +404,700 (0.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ORIC insider transactions
latest 18| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-24 | Dominic Piscitelli | Sell | $13.51 | 52,000 | $702,520 |
| 2025-12-16 | Dominic Piscitelli | Sell | $9.06 | 10,720 | $97,123 |
| 2025-12-16 | Jacob Chacko | Sell | $9.06 | 33,374 | $302,368 |
| 2025-12-16 | Pratik S Multani | Sell | $9.06 | 10,720 | $97,123 |
| 2025-10-06 | Dominic Piscitelli | Sell | $14.52 | 11,000 | $159,720 |
| 2025-10-06 | Jacob Chacko | Sell | $12.32 | 37,461 | $461,520 |
| 2025-10-01 | Jacob Chacko | Sell | $12.05 | 53,001 | $638,662 |
| 2025-09-30 | Jacob Chacko | Sell | $12.01 | 34,538 | $414,801 |
| 2025-09-22 | Jacob Chacko | Sell | $10.80 | 125,000 | $1.4M |
| 2025-06-24 | Dominic Piscitelli | Sell | $10.50 | 32,466 | $340,893 |
| 2025-06-23 | Angie You | Buy | $9.43 | 1,403 | $13,230 |
| 2025-06-23 | Dominic Piscitelli | Sell | $10.00 | 1,034 | $10,340 |
| 2025-06-20 | Angie You | Buy | $9.39 | 26,597 | $249,746 |
| 2025-06-12 | Dominic Piscitelli | Sell | $10.00 | 300 | $3,000 |
| 2025-06-11 | Dominic Piscitelli | Sell | $10.01 | 2,976 | $29,790 |
| 2025-06-10 | Dominic Piscitelli | Sell | $10.00 | 324 | $3,240 |
| 2025-06-09 | Dominic Piscitelli | Sell | $10.00 | 300 | $3,000 |
| 2025-06-06 | Dominic Piscitelli | Sell | $10.01 | 2,600 | $26,026 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ORIC shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ORIC
Institutional investors own 123.4% of ORIC Pharmaceuticals's shares and insiders 1.59%. The largest holder is Nextech Invest, Ltd. with 6.91% of the shares (7.2M), as of June 30, 2026. Among the top 20 institutions, 10 added shares and 3 reduced their stake in the latest filings. Short interest is 15.91% of the float, or 11.16 days of average trading volume. The share count rose 4,289.7% since 2018.
Related: ORIC analyst forecast, ORIC key metrics. See the ORIC stock overview for the latest quote and news.
ORIC ownership FAQ
Who owns the most ORIC Pharmaceuticals stock?
The largest shareholders of ORIC Pharmaceuticals are Nextech Invest, Ltd. (6.91%), BlackRock Inc (6.58%), EcoR1 Capital, LLC (6.49%), T. Rowe Price Associates, Inc. (6.38%), Viking Global Investors LP (4.95%).
What percentage of ORIC Pharmaceuticals is owned by institutions?
Institutions hold 123.4% of ORIC Pharmaceuticals's shares outstanding; insiders hold 1.59%.
Which funds own ORIC Pharmaceuticals?
The largest fund holders of ORIC Pharmaceuticals are Vanguard MStar Total Stk Mkt Idx Invest (2.86%), State Street® SPDR® S&P® Biotech ETF (2.35%), iShares Russell 2000 ETF (1.87%), ACAP Strategic A (1.79%), T. Rowe Price Integrated US Sm Gr Eq (1.22%).
What is ORIC Pharmaceuticals's short interest?
16.3M shares of ORIC Pharmaceuticals were sold short, 15.91% of the float; at the average daily volume it would take 11.16 days to cover.
Are insiders buying or selling ORIC Pharmaceuticals?
Of the latest 18 reported insider transactions in ORIC Pharmaceuticals (since June 6, 2025), 2 were purchases and 16 were sales.
How many shares of ORIC Pharmaceuticals are outstanding?
ORIC Pharmaceuticals has 103.7M shares outstanding, of which 88.7M are in the public float.